ANNUAL
REPORT
DRIVEN TO
MAKE A
DIFFERENCE
Through the dedication and hard work of over 1,100 employees, we continued to deliver flexible, single-use bioprocessing solutions to customers around the globe in 2020. Our focus on innovation continued to differentiate us in the bioprocessing market and helped to deliver strong financial performance. This 2020 annual report is dedicated to our unwavering team, driven to make a difference by supporting advances in biologics that are improving the lives of patients worldwide.
BUSINESS HIGHLIGHTS 2020
22
$366M | 36% | $46M |
reported | revenue growth, | revenue from |
revenue | 29% organic growth | COVID-19 |
related programs |
$54M | 55% | $717M |
revenue from cell | increase in | cash and cash |
& gene therapy | adjusted fully | equivalents at |
accounts | diluted EPS | year end |
3 | 3 | 115K |
key acquisitions | total number | increase in |
to expand our | of new product | square footage |
Systems strategy | launches | of Repligen sites |
worldwide |
3
4
Attachments
- Original document
- Permalink
Disclaimer
Repligen Corporation published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2021 16:10:05 UTC.